PRTA Prothena Corp Public Ltd Co

Price (delayed)

$57.65

Market cap

$2.55B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.1

Enterprise value

$2.22B

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating ...

Highlights
Prothena's debt has decreased by 24% YoY and by 7% from the previous quarter
The company's gross profit rose by 13% YoY and by 2.2% QoQ
The quick ratio has declined by 29% year-on-year but it has increased by 28% since the previous quarter
The company's equity rose by 27% QoQ but it fell by 8% YoY
The net income has plunged by 55% YoY and by 12% from the previous quarter
The company's EPS has shrunk by 53% YoY and by 12% QoQ

Key stats

What are the main financial stats of PRTA
Market
Shares outstanding
44.18M
Market cap
$2.55B
Enterprise value
$2.22B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.83
Price to sales (P/S)
2,661.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,544.6
Earnings
Revenue
$872,000
EBIT
-$119.77M
EBITDA
-$112.82M
Free cash flow
-$91.08M
Per share
EPS
-$3.1
Free cash flow per share
-$2.26
Book value per share
$5.87
Revenue per share
$0.02
TBVPS
$9.43
Balance sheet
Total assets
$379.72M
Total liabilities
$145.14M
Debt
$16.5M
Equity
$234.58M
Working capital
$328.85M
Liquidity
Debt to equity
0.07
Current ratio
15.02
Quick ratio
14.68
Net debt/EBITDA
2.91
Margins
EBITDA margin
-12,937.5%
Gross margin
100%
Net margin
-14,255.7%
Operating margin
-13,760.9%
Efficiency
Return on assets
-34.4%
Return on equity
-57.6%
Return on invested capital
-340%
Return on capital employed
-33.6%
Return on sales
-13,734.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRTA stock price

How has the Prothena stock price performed over time
Intraday
10.93%
1 week
48.05%
1 month
150.87%
1 year
492.5%
YTD
380.02%
QTD
129.5%

Financial performance

How have Prothena's revenue and profit performed over time
Revenue
$872,000
Gross profit
$872,000
Operating income
-$120M
Net income
-$124.31M
Gross margin
100%
Net margin
-14,255.7%
The net income has plunged by 55% YoY and by 12% from the previous quarter
Prothena's operating income has decreased by 37% YoY and by 6% QoQ
Prothena's net margin has decreased by 36% YoY and by 9% from the previous quarter
The operating margin is down by 21% year-on-year and by 4.1% since the previous quarter

Growth

What is Prothena's growth rate over time

Valuation

What is Prothena stock price valuation
P/E
N/A
P/B
9.83
P/S
2,661.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,544.6
The company's EPS has shrunk by 53% YoY and by 12% QoQ
The company's equity rose by 27% QoQ but it fell by 8% YoY
Prothena's revenue has increased by 13% YoY and by 2.2% from the previous quarter

Efficiency

How efficient is Prothena business performance
The ROIC has plunged by 125% YoY and by 25% from the previous quarter
The ROE has plunged by 101% YoY and by 15% from the previous quarter
Prothena's return on assets has shrunk by 85% YoY and by 14% QoQ
The company's return on sales fell by 31% YoY and by 5% QoQ

Dividends

What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRTA.

Financial health

How did Prothena financials performed over time
The total assets is 162% more than the total liabilities
PRTA's current ratio is up by 30% since the previous quarter but it is down by 29% year-on-year
The quick ratio has declined by 29% year-on-year but it has increased by 28% since the previous quarter
Prothena's debt is 93% less than its equity
Prothena's debt to equity has decreased by 30% QoQ and by 22% YoY
The company's equity rose by 27% QoQ but it fell by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.